Sanofi has issued the following update to its statement:
Patients may find that their normal tablet or granule preparation is substituted by their doctor for a liquid or syrup preparation of valproate and vice versa. This may result in a change to the frequency of dosing, but it is important that patients continue taking their medication and any changes are discussed with their doctor.
Original story 7 February 2019
In response to concerns about stock levels of Sanofi valproate-based medicines (Epilim and Depakote), Sanofi has issued the following statement:
Sanofi valproate out of stock statement – February 2019
Sanofi can confirm that supply of valproate (Epilim and Depakote) is available in the UK. Any patients who have concerns should contact their pharmacist who can contact the Sanofi customer service team so that we can assist and help resolve the issue.
Due to temporary disruption in the production of valproate at a Sanofi manufacturing site outside of the UK, stock levels for some treatments of valproate may be lower than usual. Sanofi is managing the situation carefully and working to ensure continued supply of valproate across all markets, including the UK. There are 17 different valproate-based treatments, ranging from tablets of different strengths and coatings through to granules and liquid preparations. We have notified the Department of Health & Social Care about the disruption of supply of valproate.
This temporary disruption in supply of some valproate-based treatments is not related to Brexit.
Change from 100 tablet packs to 30 tablet packs: At the request of the Medicines and Healthcare products Regulatory Agency (MHRA) pack sizes of valproate have been changed from 100 to 30 tablets. Pharmacies may therefore see that the 100 tablet packs are “unavailable” and assume that valproate is out of stock. The codes for 30 tablet packs should be used. The Customer Services line is available for pharmacists to check on stock levels and ordering codes.